Compare Cassava Sciences Inc (FLNA) vs Levi Strauss & Co. (LEVI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cassava Sciences Inc vs Levi Strauss & Co. — how do they compare? Cassava Sciences Inc trades at $1.07 (market cap $53.14M), while Levi Strauss & Co. trades at $24.8 (market cap $9.19B). The key difference: Levi Strauss & Co. is far larger — about 172.9× Cassava Sciences Inc's market cap, and Levi Strauss & Co. pays a 2.68% dividend while Cassava Sciences Inc pays none. Which is the better fit depends on your goals.
| FLNA | LEVI | |
|---|---|---|
Market Cap | $53.14M | $9.19B |
Sector | Health | Consumer Cyclical |
52-Week High | $4.64 | $24.83 |
52-Week Low | $1.09 | $17.92 |
Enterprise Value | -$33.43M | $10.51B |
Dividend Yield | — | 2.68% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FLNA trades at $1.06, down 2.75% today, with a bearish technical signal from moving averages but neutral oscillators. The stock shows a low P/B of 0.78, yet profitability metrics are negative, including a -79.59% ROE and -$90.97M net income for 2025. Recent Q1 2026 earnings beat expectations, and analyst consensus is 66.7% buy. News highlights Q1 financial results and a scientific presentation on TSC-related epilepsy therapies.
Outlook remains speculative due to persistent losses and negative cash flows, offset by strong analyst support and recent earnings beats. Key risks include funding needs for drug development and competitive pressures, while potential upside hinges on clinical progress in TSC-related epilepsy treatments.
Levi Strauss & Co. (LEVI) trades at $23.79, down 1.65% on the day, with a bearish technical signal despite strong fundamentals. The company reported Q2 2026 EPS of $0.28, beating expectations of $0.24, and raised its full-year outlook. Analyst consensus is strongly bullish with 15 buy ratings and a $28.00 price target. Recent dividend increases and robust digital strategy execution highlight operational strength, though stock performance faces near-term pressure from tariff and forex concerns.
Outlook remains positive with earnings momentum and strategic initiatives driving growth, but investors face risks from macroeconomic volatility and competitive pressures. The stock offers potential upside to consensus targets if execution continues, though technical weakness suggests cautious entry timing. Balanced risk-reward with fundamental support outweighing short-term sentiment headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →About Levi Strauss & Co.
Levi Strauss & Co is involved in designing, marketing, and selling products that include jeans, casual and dresses pants, tops, shorts, skirts, jackets, footwear, and related accessories directly or through third parties and licensees for men, women, and children under Levi's, Dockers, Signature by Levi Strauss & Co. and Denizen brands. The company manages its business according to three regional segments: the Americas, which is the key revenue driver
Read more on LEVI →
